Association of POLR2E rs3787016 polymorphism with lung cancer risk and efficacy of platinum-based chemotherapy: A case-control study

Abstract

Introduction: Lung cancer is one of the most prevalent cancers, with high mortality rate. Chemotherapy is a fundamental component of the treatment. However, the response varies among individuals.

Objective: This study investigated the association of the POLR2Ers3787016 polymorphism with lung cancer susceptibility and platinum-based chemotherapy response.

Methods: The study included 498 pulmonary carcinoma patients and 213 healthy individuals. Of these, 467 cases received at least two cycles of platinum-based chemotherapy The POLR2Ers3787016 genotyping was performed using time-of-flight mass spectrometry. Unconditional logistic regression analyses were used to evaluate the association of the genotype with pulmonary carcinoma susceptibility, as well as platinum-based chemotherapy response.

Results: The study found no statistically significant association between POLR2Ers3787016 and susceptibility to pulmonary carcinoma (additive model: adjusted OR [aOR] = 1.012, 95% confidence interval [CI] = 0.781-1.310, p=0.930; dominant model: aOR = 0.794, 95% CI = 0.518-1.217, p=0.289; recessive model: aOR = 1.303, 95% CI = 0.847-2.003, p=0.228). Logistic regression analysis demonstrated no meaningful association between POLR2Ers3787016 and the efficacy of platinum-based chemotherapy (additive model: aOR = 0.901, 95% CI = 0.688-1.181, p=0.450; dominant model: aOR = 0.900, 95% CI = 0.578-1.401, p=0.642; recessive model: aOR = 0.840, 95% CI = 0.541-1.306, p=0.439). Besides, no substantial association was found between POLR2Ers3787016 polymorphism and the 5-year overall survival.

Conclusion: Current evidence does not support POLR2Ers3787016 as a potential biomarker for predicting susceptibility to pulmonary carcinoma and the therapeutic efficacy of platinum-based chemotherapy in Chinese patients.

Keywords

POLR2E rs3787016 / Pulmonary carcinoma / Platinum-based chemotherapy / Cancer risk

References

[1] Oliver AL. Lung cancer: Epidemiology and screening. Surg Clin North Am. 2022; 102:335-344. doi: 10.1016/j.suc.2021.12.001

[2] Jenkins R, Walker J, Roy UB. 2022 cancer statistics: Focus on lung cancer. Future Oncol. 2023; 1-11. doi: 10.2217/fon-2022-1214

[3] Jakobsen E, Olsen KE, Bliddal M, Hornbak M, Persson GF, Green A. Forecasting lung cancer incidence, mortality, and prevalence to year 2030. BMC Cancer. 2021; 21:985. doi: 10.1186/s12885-021-08696-6

[4] Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021; 398:535-554. doi: 10.1016/S0140-6736(21)00312-3

[5] Li C, Wang H, Jiang Y, et al. Advances in lung cancer screening and early detection. Cancer Biol Med. 2022; 19:591-608. doi: 10.20892/j.issn.2095-3941.2021.0690

[6] Deshpand R, Chandra M, Rauthan A. Evolving trends in lung cancer: Epidemiology, diagnosis, and management. Indian J Cancer. 2022; 59:S90-S105. doi: 10.4103/ijc.ijc_52_21

[7] Harethardottir H, Jonsson S, Gunnarsson O, et al. Advances in lung cancer diagnosis and treatment - a review. Laeknabladid. 2022; 108:17-29. doi: 10.17992/lbl.2022.01.671

[8] Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021; 22:8661.doi: 10.3390/ijms22168661

[9] Hsiao SH, Chen WT, Chung CL, et al. Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung. Cancer Med. 2022; 11:2067-2078. doi: 10.1002/cam4.4570

[10] Szejniuk WM, Cekala M, Bogsted M, et al. Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay. Cancer Treat Res Commun. 2021; 27:100318. doi: 10.1016/j.ctarc.2021.100318

[11] Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer. 2019; 135:196-204. doi: 10.1016/j.lungcan.2019.07.010

[12] Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: First-line and second-line treatment options. J Clin Oncol. 2022; 40:671-680. doi: 10.1200/jco.21.01881

[13] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70:7-30. doi: 10.3322/caac.21763

[14] Gong WJ, Ma LY, Hu L, et al. STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy. Int J Clin Oncol. 2019; 24:476-84. doi: 10.1007/s10147-018-01386-7

[15] Szejniuk WM, Robles AI, McCulloch T, Falkmer UGI, Roe OD. Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art. Pharmacogenomics J. 2019; 19:5-14. doi: 10.1038/s41397-018-0029-1

[16] Thissen D, Steinberg L, Kuang D. Quick and easy implementation of the Benjamini-Hochberg procedure for controlling the false positive rate in multiple comparisons. J Educ Behav Stat. 2002; 27:77-83. doi: 10.3102/10769986027001077

[17] McKay J, Tenet V, Franceschi S, et al. Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study. PLoS One. 2017; 12:e0177775. doi: 10.1371/journal.pone.0177775

[18] Champely S. PWR: Basic Functions for Power Analysis. R Package Version 1.3-0; 2020. Available from:https://github.com/heliosdrm/pwr [Last accessed on 2024 Jun 05].

[19] Chen B, Jiao Y, Yaolong F, et al. The POLR2E rs3787016 polymorphism is strongly associated with the risk of female breast and cervical cancer. Pathol Res Pract. 2019; 215:1061-1065. doi: 10.1016/j.prp.2019.02.015

[20] Gong WJ, Peng JB, Yin JY, et al. Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol Sin. 2017; 38:581-590. doi: 10.1038/aps.2016.164

[21] Zhang YK, Wu LL, Li TT, Cao DY, Zheng Q, Liu L. The POLR2E rs3787016 polymorphism is associated with susceptibility to and prognosis of gastric cancer. Neoplasma. 2021; 68:665-71. doi: 10.4149/neo_2021_201125N1277

[22] Huang S, Cui H, Lou Z, et al. Association of rs3787016 in long non-coding RNAs POLR2E and rs2910164 in MiRNA- 146a with prostate cancer: A systematic review and meta-analysis. Iran J Public Health. 2018; 47:623-632.

[23] Chen B, Wang S, Ma G, et al. The association of POLR2E rs3787016 polymorphism and cancer risk: A Chinese case-control study and meta-analysis. Biosci Rep. 2018;38:BSR20180853. doi: 10.1042/BSR20180853

[24] Chen B, Li J, Yi C, Jiao Y, Gu X, Feng X. Long non-coding RNA POLR2E rs3787016 is associated with the risk of papillary thyroid carcinoma in Chinese population. Pathol Res Pract. 2018; 214:1040-1044. doi: 10.1016/j.prp.2018.04.008

[25] Kang M, Sang Y, Gu H, et al. Long noncoding RNAs POLR2E rs3787016 C/T and HULC rs7763881 A/C polymorphisms are associated with decreased risk of esophageal cancer. Tumour Biol. 2015; 36:6401-6408. doi: 10.1007/s13277-015-3328-z

[26] Baili E, Gazouli M, Lazaris AC, et al. Associations of long non-coding RNAs HOTAIR, LINC00951, POLR2E and HULC polymorphisms with the risk of esophageal and esophagogastric junction cancer in a western population: A case-control study. Mol Biol Rep. 2024; 51:249. doi: 10.1007/s11033-024-09206-0

[27] Yu J, Lan L, Liu C, Zhu X. Improved prediction of prognosis and therapy response for lung adenocarcinoma after identification of DNA-directed RNA polymerase-associated lncRNAs. J Cancer Res Clin Oncol. 2023; 149:12737-12754. doi: 10.1007/s00432-023-05118-x

[28] Liu Q, Li Z, Li N, Liu J, Wu H, Chen J. Nucleic acid-sensing-related gene signature in predicting prognosis and treatment efficiency of small cell lung cancer patients. Front Oncol. 2024; 14:1394286. doi: 10.3389/fonc.2024.1394286